Novan Completes Funding Transaction with Ligand Pharmaceuticals
06 mai 2019 09h00 HE
|
Novan, Inc.
Novan to immediately receive $12 million of non-dilutive capitalLigand to receive milestones and tiered royalty for North America SB206 molluscum indicationPhase 3 molluscum trial to begin recruitment...
Novan Confirms Corporate Update Conference Call and Webcast
01 mai 2019 08h15 HE
|
Novan, Inc.
MORRISVILLE, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019...
Novan Secures Up to $35 Million in Non-Dilutive Funding
29 avr. 2019 16h15 HE
|
Novan, Inc.
$25 million provided immediately in exchange for participation in future potential cash flows Additional $10 million available upon achieving success in molluscum Phase 3 top line resultsPipeline...
Novan and Sato Advance Japan Market and Dermatology Partnership
19 mars 2019 09h00 HE
|
Novan, Inc.
Dr. Elizabeth Messersmith named chairperson of the Sato and Novan Joint CommitteeSimultaneous clinical development progress for SB206 in Japan and US underwayNovan receives second installment of $4.5...
Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
11 mars 2019 08h00 HE
|
Novan, Inc.
Completed end-of-Phase 2 FDA meeting for molluscum contagiosumMeeting minutes received and support second quarter 2019 pivotal Phase 3 initiationFinalizing establishment of Irish entity to enable EU...
Novan Provides Business Update
30 janv. 2019 16h15 HE
|
Novan, Inc.
End-of-Phase 2 meeting with FDA for molluscum granted and scheduled for early MarchActive business development discussions ongoing around certain late-stage assets and broader dermatology platformDr....
Novan Announces Management Changes and Provides Business Update
02 janv. 2019 06h15 HE
|
Novan, Inc.
Paula Brown Stafford promoted to President and newly created role of Chief Operating Officer of Novan Dr. Carri Geer promoted to Senior Vice President and Chief Technology Officer Dr. Elizabeth...
Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
11 déc. 2018 08h00 HE
|
Novan, Inc.
Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by...
Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily
10 déc. 2018 07h30 HE
|
Novan, Inc.
SB206 12% once-daily achieved the highest rate of complete clearance out of all active treatment groups at Week 12 (p<0.05)Statistically significant reductions in molluscum lesions as early as Week...
Novan to Present at Piper Jaffray 30th Annual Healthcare Conference
20 nov. 2018 08h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Paula Brown Stafford, Chief Development Officer, and Nathan Stasko,...